zzz
Lv3
270 积分
2023-09-13 加入
-
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
29天前
已完结
-
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
30天前
已完结
-
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
1个月前
已完结
-
New Interleukin-23 Pathway Inhibitors in Dermatology
1个月前
已完结
-
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
1个月前
已完结
-
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
1个月前
已完结
-
Certolizumab pegol for the treatment of psoriasis
2个月前
已完结
-
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
2个月前
已完结
-
Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis
3个月前
已完结
-
Psoriasis and the metabolic syndrome
6个月前
已完结